AN ADJUVANT COMPOSITION INTENDED FOR TREATMENT OF LEUKEMIA
Creators: name: Alkoclar, Erdal Can
Publisher: name: Zenodo
Year: 2020
Subjects: JNK MAPK FCER1A

description: The present invention herewith is related to a composition developed for symptomatic treatment of Leukemia <strong>Background of the Related Technology</strong> At present it is known that Leukemia is a cancer type that is diagnosed with abnormal increase of the blood cells, especially leukocytes. The high number of immature and malign cells replacing the normal marrow cells, will result in damages to the marrow. This will lead to a decrease in the number of platelets, which play an important role in blood clotting and a decrease in number of leukocytes, which play an important role in body defense. This will eventually cause frequent injuries and bleeding in Leukemia patients, which then will easily lead to infections in patients. The defense mechanism weakens. In later stages, reduction in red blood cells may cause anemia and difficulty in breathing. Besides these, other symptoms observed are weakness and fatigue, fever, certain neurological symptoms and inflammation and bleeding of gums. Again today, we know that Leukemia is a cancer that affects the blood producing system in the body (lymphatic system and bone marrow). Leukemia is classified as acute and chronic (which is then divided into sub-groups depending on the shapes observed through a microscope) and also according to the characteristics of progress and spreading of the tumor. In general while acute Leukemia is observed more in infants, there is a greater tendency of chronic leukemia developing in adults. Based on the information related to the technology, there are various types of blood cancers, depending on the type of the cells (e.g. myeloid, lymphoid) and period of the disease (chronic and acute). The progress of certain types of leukemia is quite fast and bad. The infant Leukemia types are observed more frequently when compared to other cancer types. While the exact cause in not known, it is believed that both genetic and environmental factors play a major role. Mutations in DNA’s of somatic cells cause the oncogenes to become active or the tumor suppressing genes to become inactive. Thus the regulation of cell death and division is damaged. Besides genetic factors, it is considered that certain petrochemicals, radiation, carcinogenic material and certain viruses (e.g. HIV) lead to the referred damages The invention presented herewith with no "WO 2000/027428", with title "Treatment of Hematologically Malignant Cells Related to Circulating Tumor Cells by Using Chimeric CD20-Inhibiting Antibodies” and under classification number "A61K 39/00", is related to a method of treating hematologically malignant cells related to the high number of circulating tumor cells by administrating therapeutically virtual CD20-inhibiting antibodies as medicine. Such malignant types specifically include B- prolymphocytic Leukemia (B-PLL), chronic lymphocytic Leukemia (CLL), and transformed non-Hodgkin’s lymphoma. Again the invention presented herewith with no "WO 2000/031055", with title "5-[{6-(2-Fluorobenzyl)oxy-2-naphtyl}methyl]-2,4-thiazolidine dione Crystals" and under classification number "C07D 277/34", is related to stable and new C type crystals of 5-[{6-(2-Fluorobenzyl)oxy-2-naphtyl}methyl]-2,4-thiazolidine dione and these are fit to be used as therapeutically active components for treatment of below diseases; diabetes and its complications, hyperlipidemia and its complications Again the invention presented herewith with no "EP1643984B1", with title "Using Parthenolide Derivatives as Anti-leukemic and Cytotoxic Agents” and under classification number "A61K 31/14", is related to methods for structural modifications of sesquiterpene lactone, parthenolide and derivatives of this parthenolide, which are used in treatment of malignant tumors. Specifically, the present invention herewith is related to methods of producing new pharmaceutically active chemicals that have increased water solubility characteristics and of preparing parental compositions and structural analogues of parthenolide, with the intention to use such chemicals in treatment of leukemia and other human cancers that display parenteral and multiple drug resistance. Again the invention presented herewith with no “EP2139882B1", with title " 3-Substituted Quinoline or Quinoxaline Derivatives and Using These as Phosphatidylinositol 3-Kinase (pı3k) Inhibitors" and under classification number “C07D 401/12", is related to the substituted bicyclic heteroaryl compounds having the structure shown in (I) or their pharmaceutically acceptable salts and compositions consisting of these, where X variable means C or N, and Y variable means N(R"), O or S, and referred compounds are useful in inhibiting the biological activity of PI3K5 enzyme of human origin and are intended for using treatment of general inflammation, arthritis, rheumatoid diseases, osteoarthritis, inflammatory intestinal disorders, inflammatory eye diseases, inflammatory and unstable bladder disorders, psoriasis, dermal complaints consisting of inflammatory components, chronic inflammatory cases, for example autoimmune diseases including but not limited with, systemic lupus erythematosus (SLE), myasthenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis, Sjogren’s Syndrome and autoimmune hemolytic anemia, and also treatment of allergic cases including all hypersensitivity forms. On the other hand, with the present invention methods are provided that are intended for treatment of cancer cases that develop through p1105 activity, depends on p1105 activity or is related to p1105 activity, including but not limited with, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Myeloproliferative Diseases (MPD), Chronic Myeloid Leukemia (CML), T-Cell Acute Lymphoblastic Leukemia (T-ALL), B-Cell Acute Lymphoblastic Leukemia (B-ALL), Non-Hodgkin’s Lymphoma (NHL), B-cell lymphoma and solid tumors like breast cancer.. To conclude it has become inevitable to proceed with a development in the area of the related technology, considering the inadequacy of the existing solutions and the need for a composition intended for treatment of Leukemia. <strong>Objective of the Invention</strong> To overcome the disadvantages referred in the Background of the Related Technology, One objective of the present invention is, (CCL1) gene expression suppression; One other objective of the invention is CCL2 gene expression suppression One other objective of the invention is CCL3 gene expression suppression; One other objective of the invention is CCL4 gene expression suppression; One other objective of the invention is FCER1A gene expression suppression; One other objective of the invention is NFATC1 gene expression suppression; One other objective of the invention is MAPK expression suppression; One other objective of the invention is JNK phosphorylation suppression. The present invention which is aimed to achieve the above-mentioned advantages, is intended for treatment of Leukemia and is a composition that is obtained by combination of the compositions selected in a single form or in combinations from a group containing; 6-beta-(16,20)-stigmast-6-ene-phenyl-4-one, 7-alpha-(17,20)-stigmast-6-ene-phenyl-4-one, 7-oxo-(3β,7B,25R)-spirost-5-ene-3-trione, (24R)-spirost-5-ene-3β,7β,10α-diol, 7-beta-glucopyranoside, 3,5-bis-alpha-L-ramnopyranosyl)-(16,20)-beta-D-methoxypyranosite. Structural and characteristic properties as well as all the advantages of the invention presented herewith will be clearly understood with the detailed description provided below and thus the evaluation regarding the present invention should be based on the detailed description presented herewith. <strong>Detailed Description of the Invention</strong> The present invention is related to a composition developed for treatment of Leukemia. The referred composition suppresses (CCL1) gene expression, suppresses CCL2 gene expression, suppresses CCL3 gene expression, suppresses CCL4 gene expression, suppresses FCER1A gene expression, suppresses NFATC1 gene expression, suppresses MAPK expression, suppresses JNK phosphorylation . The composition related to the present invention herewith contains; 6-beta-(16,20)-stigmast-6-ene-phenyl-4-one, 7-alpha-(17,20)-stigmast-6-ene-phenyl-4-one, 7-oxo-(3β,7B,25R)-spirost-5-ene-3-trione, (24R)-spirost-5-ene-3β,7β,10α-diol, 7-beta-glucopyranoside, 3,5-bis-alpha-L-ramnopyranosyl)-(16,20)-beta-D-methoxy-pyranosite. The referred formulation is formed by mixing the above-mentioned components at below percentages by weight; 11-15% of 6-beta-(16,20)-stigmast-6-ene-phenyl-4-one, 22-18% of 7-alpha-(17,20)-stigmast-6-ene-phenyl-4-one, 3-17% of 7-oxo-(3β,7B,25R)-spirost-5-ene-3-trione, 14-10% of (24R)-spirost-5-ene-3β,7β,10α-diol, 20-30% of 7-beta-glucopyranoside, 30-10%of 3,5-bis-alpha-L-ramnopyranosyl)-(16,20)-beta-D-methoxypyrano-site. Components given above are obtained by combining the components from the above-mentioned group at the given range of weight ratios in a single form or in combinations thereof. The present invention at the same time is related to using the above-referred composition for treatment of leukemia and manufacturing it for such purpose <strong>CLAIMS</strong> A composition intended for treatment of Leukemia, which consists of combining the components selected from the group; 6-beta-(16,20)-stigmast-6-ene-phenyl-4-one, 7-alpha-(17,20)-stigmast-6-ene-phenyl-4-one, 7-oxo-(3β,7B,25R)-spirost-5-ene-3-trione, (24R)-spirost-5-ene-3β,7β,10α-diol, 7-beta-glucopyranoside, 3,5-bis-alpha-L-ramnopyranosyl)-(16,20)-beta-D-methoxypyranosite in a single form or in combinations thereof. The composition of Claim 1 which is characterized by containing 11-15% of 6-beta-(16,20)-stigmast-6-ene-phenyl-4-one by weight. The composition of Claim 1 which is characterized by containing 22-18% of 7-alpha-(17,20)-stigmast-6-ene-phenyl-4-one by weight. The composition of Claim 1 which is characterized by containing 3-17% of 7-oxo-(3β,7B,25R)-spirost-5-ene-3-trione by weight. The composition of Claim 1 which is characterized by containing 14-10% of (24R)-spirost-5-ene-3β,7β,10α-diol by weight. The composition of Claim 1 which is characterized by containing 20-30% of 7-beta-glucopyranoside by weight. The composition of Claim 1 which is characterized by containing 30-10%of 3,5-bis-alpha-L-ramnopyranosyl)-(16,20)-beta-D-methoxypyranosite by weight. Using the compositions obtained by selecting singly or in combination of components from the group of; 6-beta-(16,20)-stigmast-6-ene-phenyl-4-one, 7-alpha-(17,20)-stigmast-6-ene-phenyl-4-one, 7-oxo-(3β,7B,25R)-spirost-5-ene-3-trione, (24R)-spirost-5-ene-3β,7β,10α-diol, 7-beta-glucopyranoside, 3,5-bis-alpha-L-ramnopyranosyl)-(16,20)-beta-D-methoxypyranosite from any one as given in Claims 2-7 in manufacturing the composition intended for treatment of Leukemia. <strong>SUMMARY</strong> <strong>AN ADJUVANT COMPOSITION INTENDED FOR TREATMENT OF LEUKEMIA</strong> The present invention is related to a composition developed for treatment of Leukemia. The referred composition suppresses (CCL1) gene expression, suppresses CCL2 gene expression, suppresses CCL3 gene expression, suppresses CCL4 gene expression, suppresses FCER1A gene expression, suppresses NFATC1 gene expression, suppresses MAPK expression, suppresses JNK phosphorylation.